Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

Fineline Cube Jan 14, 2026
Company Deals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Fineline Cube Jan 14, 2026
Company Deals

Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund

Fineline Cube Jan 14, 2026
Company Deals

Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases

Fineline Cube Jan 14, 2026
Company Deals

Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital

Fineline Cube Jan 14, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination

Fineline Cube Jan 14, 2026
Company Drug

Henlius’s HANBEITAI Bevacizumab Biosimilar BLA Accepted by FDA for Multiple Solid Tumors

Fineline Cube Jan 14, 2026
R&D

Beijing Launches Bio-Park: A New Hub for International Pharmaceutical Innovation

Fineline Cube Jul 22, 2024

Beijing has unveiled an ambitious plan to construct Bio-Park, a state-of-the-art international pharmaceutical innovation park...

Company Deals Medical Device

MicroPort CardioFlow Secures Exclusive Distribution Rights for Evermend Occluders in China

Fineline Cube Jul 22, 2024

MicroPort Scientific Corp (HKG: 0853), a leading medical device company based in China, has announced...

Policy / Regulatory

China’s NMPA and NHC Implement New Rules for Temporary Import of Urgent Medical Devices

Fineline Cube Jul 22, 2024

The National Medical Products Administration (NMPA) and the National Health Commission have issued the Management...

Company Deals Drug

Jiangsu QYuns Therapeutics and Huadong Medicine Partner on QX005N Injection Development and Promotion

Fineline Cube Jul 22, 2024

Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509), a biopharmaceutical company based in China, has entered...

Company Drug

Innovent Biologics’ Mazdutide Achieves Primary and Secondary Endpoints in Phase III T2D Trial

Fineline Cube Jul 22, 2024

Innovent Biologics Inc. (Innovent) (HKG: 1801), a leading biopharmaceutical company based in China, has announced...

Policy / Regulatory

China Unveils Ambitious Healthcare Reforms at 20th Central Committee Plenary Session

Fineline Cube Jul 22, 2024

The third plenary session of the 20th Central Committee of the Communist Party of China...

Company Drug

Jiangsu Hengrui Receives NMPA Approval to Study CDK 4/6 Inhibitor Dalpiciclib in Combination with HRS-1358 for Breast Cancer

Fineline Cube Jul 22, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has received...

Company Drug

Hansoh Pharmaceutical’s EGFR Inhibitor Ameile Files for Adjuvant Therapy Approval with NMPA

Fineline Cube Jul 22, 2024

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading biopharmaceutical company based in China, has...

Company Drug

NMPA Approves Chengdu Chipscreen’s Bilessglu for Type 2 Diabetes in Combination with Metformin

Fineline Cube Jul 22, 2024

The National Medical Products Administration (NMPA) has granted approval for Shenzhen Chipscreen Biosciences Co., Ltd...

Company Deals

Eisai Forges Partnerships with Chinese Firms to Strengthen Alzheimer’s Disease Market Presence

Fineline Cube Jul 22, 2024

Eisai Co., Ltd, (TYO: 4523) a Japanese pharmaceutical company, has announced separate strategic partnerships with...

Company Deals

MedSci Healthcare’s Bioon.com Partners with Wego Group to Boost Local Innovation and Product Promotion

Fineline Cube Jul 22, 2024

MedSci Healthcare Co., Ltd (HKG: 2415), a Chinese healthcare company, has announced that its subsidiary,...

Company Deals

Rona Therapeutics Secures USD 35 Million in Series A+ Round to Advance Nucleic Acid Therapies

Fineline Cube Jul 22, 2024

Rona Therapeutics, a Shanghai-based nucleic acid drug developer, has secured USD 35 million in a...

Company Deals

Huadong Medicine to Expand TCM Footprint with Acquisition of Hengba Pharmaceutical

Fineline Cube Jul 22, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced its intention to...

Company Deals

Beijing X-Magtech Secures Over RMB 100 Million in Series A+ Funding for Magnetic Field Measurement Tech

Fineline Cube Jul 22, 2024

Beijing X-Magtech Technologies, a specialist in ultra-weak magnetic field measurement technology, has reportedly secured over...

Company Deals

BGI Genomics and Technopark Biogen Launch Astana Genetic Center to Boost Genetic Testing in Central Asia

Fineline Cube Jul 22, 2024

Astana Genetic Center, a collaboration between China’s leading genomics company BGI Genomics Co., Ltd (SHE:...

Company Deals Drug

Apeiron Therapeutics Sells Rights to CDK7 Inhibitor GTAEXS617 to Exscientia for USD 30 Million

Fineline Cube Jul 22, 2024

Apeiron Therapeutics, a Shanghai-based biopharmaceutical company, has reached an agreement to sell all rights to...

Company Deals Digital Hospital

WeDoctor Partners with Shanghai Children’s Medical Center to Enhance Pediatric Care

Fineline Cube Jul 22, 2024

WeDoctor Holdings Ltd, a subsidiary of Chinese internet conglomerate Tencent Corporate Venture Capital (HKG: 0700)...

Company Drug

Bio-Thera Solutions Submits BLAs for Stelara Biosimilar BAT2206 to FDA and EMA

Fineline Cube Jul 22, 2024

Bio-Thera Solutions Ltd, a biopharmaceutical company based in Guangzhou, has announced the submission of Biologic...

Company

Novartis Delivers Strong Q2 2024 Results with 11% YoY Net Sales Increase

Fineline Cube Jul 19, 2024

Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has released its financial results for the second...

Company Deals Drug

J&J Halts Development of Epilepsy Therapy ADX71149 After Phase II Trial Failure

Fineline Cube Jul 19, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a US-based multinational medical devices, pharmaceutical, and consumer packaged...

Posts pagination

1 … 270 271 272 … 609

Recent updates

  • WuXi Biologics Secures MHRA GMP Certification for Ophthalmic Biologic Manufacturing Facilities
  • NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development
  • AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D
  • Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund
  • WuXi AppTec Projects 2025 Revenue of $6.51 Billion, Net Profit Surges 103% on Divestments
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

WuXi Biologics Secures MHRA GMP Certification for Ophthalmic Biologic Manufacturing Facilities

Company Deals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

Company Deals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Company Deals

Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.